Eligibility Multiple Sclerosis Betaferon/Betaseron NCT00099502
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients https://clinicaltrials.gov/ct2/show/NCT00099502 The purpose of this study is to determine - whether treatment with Betaferon / Betaseron (interferon beta-1b) 500 micrograms safe, tolerable and more efficacious than treatment with interferon beta-1b 250 micrograms - whether treatment with Betaferon / Betaseron (interferon beta-1b) tolerable and more efficacious than treatment with Copaxone (Glatiramer Acetate) 20 mg
Eligibility Multiple Sclerosis Betaferon/Betaseron NCT00099502
- StudyEvent: Eligibility
C0006147 (UMLS CUI [1,2])
35489007 (SNOMEDCT)
10012399 (MDR)
F34.1 (ICD10CM)
82313006 (SNOMEDCT)
10042464 (MDR)
T14.91 (ICD10CM)
E12969 (CTCAE)
789-8 (LNC)
767002 (SNOMEDCT)
10047939 (MDR)
6690-2 (LNC)
365632008 (SNOMEDCT)
777-3 (LNC)
75183008 (SNOMEDCT)
10019670 (MDR)
26091008 (SNOMEDCT)
MTHU004883 (LNC)
1920-8 (LNC)
56935002 (SNOMEDCT)
MTHU006766 (LNC)
1742-6 (LNC)
60153001 (SNOMEDCT)
MTHU001941 (LNC)
2324-2 (LNC)
75284005 (SNOMEDCT)
MTHU011411 (LNC)
2367-1 (LNC)
109983007 (SNOMEDCT)
10060880 (MDR)
D47.2 (ICD10CM)
418634005 (SNOMEDCT)
T78.40 (ICD10CM)
293639009 (SNOMEDCT)
294375008 (SNOMEDCT)
416098002 (SNOMEDCT)
10013700 (MDR)
T88.7 (ICD10CM)
DALG (HL7V3.0)
294854007 (SNOMEDCT)
387168006 (SNOMEDCT)
MTHU015736 (LNC)